MOTS-c

• Community metabolic/longevity blockrecommended

  Community practice, not from a label or trial. The lower end of the 5-10 mg range; Mon/Wed/Fri.

• Low-dose daily pattern

  Community practice, not from a label or trial: the minority 1-2 mg daily pattern, taken at the low end.

• Community practice, not from a label or trial: 5-10 mg subcutaneous 3x/week, 4-8 weeks on then 4 weeks off (the page calls the cycling precautionary, not evidence-based).
• Community: 5 mg within 60 minutes after a workout, up to 3x/week, for 4-8 weeks. A minority pattern is 1-2 mg daily.
• Mouse reference only: 0.5 mg/kg/day (Lee 2015). The source says no validated human dose exists.

Route: Subcutaneous (27-30 gauge insulin syringe per the source).

Timing: Optionally within 60 minutes after exercise (community); no trial compares timing.

• Bacteriostatic water per the source, with no volume stated. The water in the protocols is arithmetic for a readable draw (10 mg vial + 0.5 mL water gives 5 mg = 25 units), not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

4 weeks off after a 4-8 week block (community, precautionary).

Why:

• Not evidence-based; the source calls it precautionary.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.

Not FDA-approved. FDA lists MOTS-c among bulk substances that may present significant safety risks for compounding. Prohibited by WADA (S4.4 metabolic modulators) per the source.

Common side effects:

• Community reports: injection-site redness, transient swelling, occasional early-cycle fatigue. Controlled human data are missing.

Stop and call your prescriber if:

• Injection-site infection
• Symptoms of low blood sugar
• Severe fatigue or muscle weakness

No reliable source names a biomarker for this compound.

• Outliyr MOTS-c report (evidence level, community protocols, regulatory status)
• ClinicalTrials.gov NCT03998514: CB4211 (MOTS-c analog) phase 1a/1b